Human Dermal Fibroblast, Adult (HDF-Ad)

300606

□□ □□

□□

□□ □□ □□□□□, □□(HDF-Ad)□ □□ □□□ □□□□□ □□□ □□ □□□□□. □ □□□ □□ □□□ □□ □□□ □□□□ □□□□ □□□□□ □□□ □□ □ □□ □ □□ □□□□ □ □□ □□□□□ □□□ □□□ □□□□□. HDF-Ad □□□ □□ □□ □ □□ □□□□ □□□ □□□ □□ □□□ □□ □□, □□ □ □□ □□ □□ □□□ □ □ □□□□□. □□ □□□ □□□ □□ □ □□□□ □□□□□□ □□□ □□□□ □ □□□ □□□□ □□□□□.
HDF-Ad □□□ □□ □□□ □□ □□□□ □□□□□ □□□, □□ □□□□, □□□ □□ □□□□ □□ □□□ □□ □□□ □□ □□ □□□ □□□□ □ □□□ □□□ □ □ □ □□□. □□ □□□ □□□□ □□ □□□□ □□□□ □□□□ □□□ □□ □□ □□ □ □□ □□□□ □□ □□ □□ □□□ □□□□□. □□□ □□□ □□ □□□ □□ □□□ □ □□ □□□□□ □□ □ □□ □□□□ □□ □□□□ □□□□□ □□ □□□ □□□ □□□ □□□ □□□□□.

□□	Dermis

□□ □□

UVA-induced photoaging: oxidative stress, MAPK/AP-1 signaling and MMP-1 expression; Cellular senescence after UVA exposure (SA-β-gal, p16, SIRT1/mTOR signaling); Accumulation and degradation of advanced glycation end products in photoaged fibroblasts; Epigenetic regulation of MMP-1 and collagen loss in skin photoaging; Fibrosis research and systemic sclerosis (TGF-β/SMAD signaling, collagen production); Dermal compartment of reconstructed human skin for skin sensitization studies

□□□

- NHDF-Ad
- HFIB-D
- Human fibroblasts
- dermis adult
- provitro 1210411

□□□

□□□ □□	Adult
□□	□□

□□

□□□	□□
□	□□□
□□ □□	□□□
□□□□ □□	1

□□

□□□	Spindle-shaped (fibroblast-like)
□□ □□	Primary fibroblasts
□□ □□□	□□□

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

□□ □ □□

□□

MEM, □□□□□□□□□ □□□, □□□□□□□□□□□□ □□□(□ □□□ □□□□ □□□ □□ □□□□□ □□□ □□□. □□ □□□ □□□ □□ □□□□□ □□□□.)

□□ □□	37°C, 5%CO2, □□ □□.

□□□□□□

□□□ 10% FBS, 2 ng/mL hr-bFGF, 2mM □□ L-□□□□□ □□□□□

□□ □□	□□□-EDTA

□□□

□□□□ □□ □□ □□□: □□□ □□□□ □□□ □□□□ □□□□ PBS□ □□□□ □□ □□□□ □□□□□. PBS□ □□□ □ □□ □□ □□□ □□ □□□ □□ □□ □/EDTA □□□ □□□□(□: T25 □□□□□ □□ 1ml, T75 □□□□□ □□ 3ml) □□□ □□□ □□□ □□ □□ 37°C□□ □□□□□(5-10□). □□□□□ □□ □□□ □□□□ □□□ □□ □□□ □□□ □□□ □□□ □□□□□. □□□□ □□□ □□□ □□□□ □□□/EDTA□ □□□□□□ □□□ □□□□ □□ □□□□ □□ □□ □□□ □ □□ □□□ □□□ □□ □□ □ □□ □□□ □□□□. □□□ 37°C, 5%CO2□ □□□ □□□□□□ □□ 2~3□□□ □□□ □□□□□.

□□ □□	1~3×10³ □□/cm²
□□ □□	□ 2~3□
□□ □ □□	Post-thaw viability ≥ 70 % viable cells. More than 80 % confluence within the expected recovery period.

□□ □ □□

Thaw the cryovial quickly in a 37 °C water bath, swirling gently. Just before the last ice has melted, move the vial to a laminar flow hood and decontaminate its outer surface.
Transfer the cell suspension into a 15 ml centrifuge tube, add 10 ml of Fibroblast Growth Medium and centrifuge at 250 × g for 5 minutes.
Remove the supernatant and resuspend the cell pellet in 10 ml of Fibroblast Growth Medium. Check cell number and viability.
Divide the suspension between two 25 cm² culture flasks (5 ml each). Using two flasks reduces the risk of losing all cells if a passage fails.
Incubate at 37 °C, 5 % CO_2 and saturated humidity, with the screw caps opened by half a turn for gas exchange.
Change the medium after 24 hours to remove unattached cells, then every 48 to 72 hours, using pre-warmed medium only.
Subculture the cells at about 75 % confluence. Denser cultures undergo irreversible contact inhibition and stop proliferating. Use the subculture reagents recommended on the certificate of analysis.
Recommended seeding density: more than 4,000 cells/cm².

□□ □□ □ □□ □□

□□

□□□□□□□ □□□ PCR □□ □□□□ □□ □□ □□□□□□□ □□□□ □□ □□□□ □□□□□.
□□□□, □□□ □□ □□ □□□ □□□ □□□□ □□ □□ □□□ □□ □□ □□□ □□□□.

□□□ □□	□□ □□ □□□ 90% FBS + 10% DMSO□ □□□□ □□□□ □□□□□, □□□□ □□ □□□ □ □□ □□ □□ □□□□ CM-1(Cytion □□□□ □□ 800100)□ □□□□ □□□□ □□□ □□□□ □□ □□□□□ □□ □□.

□□ □□

□□ □□□ □□□□ □□□□ □ -150°C□□ -196°C□ □□□ □□ □□□ □□□□. 80°C□□ □□□□ □□ □□ □□□ □□□ □ □□ □□ □□□□ □□□□□.

□□ □□

□□ □□ □□□□ □□ □ □ -78°C□ □□□ □ □□ □□□ □□□ □□□ □□□ □□ □□□ □□□□□□□ □□ □□□□□. □□ □□ □□□ □□□□ □□□□ □□ □□ □ □□ □□ □□□ □□□□.

□□ □ □□□

□□ □□

CD90⁺, CD31⁻, CD45⁻

□□□ □□

□□: CD73/CD90/CD105 □□: CD14/CD34/CD45/HLA-DR

□□□□

□□□ □□ □□: HIV-1/2, HBV, HCV, HSV1/2, CMV, EBV, HHV6, □□□□□ □□□, □□□□□□ □□, □□□□□ □□□□□□, □□□□□□□ □□□□□, □□□ □□□□ □□□

□□□

□□

□□ □□ □□□□□, □□(HDF-Ad)(□□□□ □□□□ □□ 300606)

NCBI □□ □□□□	9606

□□ □ □□

□□ □□

□□ □□□ □□ □□ □□□ □□ □□□ □□□□ □□, □□□ □□ □□□ □□□□ □□□. □□□ □□ □□□ □□□ □□□□, □□ □□ □□□ □□ □□□ □□ □□ □□□ □□ □□□□ □□□□ □□□□ □□□. □□ □□ □ □□□□ □□□ □□□□ □ □□ □□□ □□□ □□ □□ □□□ □□□ □□ □□□□.

□□

□□□□□ □□□ □□□ □□□□ □□□□□.
□□□ □□ □□□□ □□□ □ 60□ □□ □□ □□ □ □□□ □□□ □ □□□ □□□□□.
□□□ □□ □□□ □□ □□□ □/□□ □□ □□□ □□□ □□□ □□□□ □□□□□
□□□ □□□ <a href=""/Who-we-are/Warranty/"" hreflang=""x-default"">□□□ □ □□□□□ □□□□

□□ □□ □□□**(MTA)**□ □□□□□**.**	Yes